Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.

被引：0
|
作者：
Sholler, Giselle Linda Saulnier
Ferguson, William
Bergendahl, Genevieve
Clinch, Thomas
Kraveka, Jacqueline M.
机构：
[1] Penn State Hlth Childrens Hosp, Hershey, PA USA
[2] St Louis Univ, St Louis, MO 63103 USA
[3] US WorldMeds, Louisville, KY USA
[4] Med Univ South Carolina, Charleston, SC 29425 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10060
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma
    Villablanca, Judith G.
    Ji, Lingyun
    Shapira-Lewinson, Adi
    Marachelian, Araz
    Shimada, Hiroyuki
    Hawkins, Randall A.
    Pampaloni, Miguel
    Lai, Hollie
    Goodarzian, Fariba
    Sposto, Richard
    Park, Julie R.
    Matthay, Katherine K.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [42] 5 Year Outcomes after Proton Therapy for Treatment of High-Risk Neuroblastoma (HR-NBL)
    Hill-Kayser, C.
    Balamuth, N.
    Womer, R.
    Maris, J.
    Mosse, Y.
    Fox, E.
    Balis, F.
    Grupp, S.
    Miller, A.
    Kurtz, G.
    Lustig, R.
    Tochner, Z.
    Bagatell, R.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S83 - S83
  • [43] Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients—role of maintenance therapy in the real world
    Moussab Damlaj
    Mohamed Tlayjeh
    Ahmad Damlaj
    Bader Alahmari
    Husam AlSadi
    Mazin Ahmed
    Zied AlJubour
    Ayman Alhejazi
    Hend Salama
    Ayman Ibrahim
    Abdulrahman Al Raizah
    Mohammed Bakkar
    Abdulraouf Ghori
    Abdullah S. Al Saleh
    Ahmed Alaskar
    Mohsen Alzahrani
    Bone Marrow Transplantation, 2023, 58 : 1160 - 1162
  • [44] Immunotherapy with ch14.18/CHO in combination with IL2 is active and effective in high-risk relapsed/refractory neuroblastoma patients
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Siebert, Nikolai
    Jensen, Christian
    Endres, Stefanie
    Pill, Lena
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Manzitti, Carla
    Mueller, Ina
    Loibner, Hans
    Ladenstein, Ruth
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [45] Treatment outcomes among high-risk neuroblastoma patients receiving non-immunotherapy regimen: Multicenter study on behalf of the Thai Pediatric Oncology Group
    Suwannaying, Kunanya
    Monsereenusorn, Chalinee
    Rujkijyanont, Piya
    Techavichit, Piti
    Phuakpet, Kamon
    Pongphitcha, Pongpak
    Chainansamit, Su-on
    Chotsampancharoen, Thirachit
    Winaichatsak, Angkana
    Traivaree, Chanchai
    Sathitsamitphong, Lalita
    Kanjanapongkul, Somjai
    Komvilaisak, Patcharee
    Sanpakit, Kleebsabai
    Photia, Apichat
    Seksarn, Panya
    Wiangnon, Surapon
    Hongeng, Suradej
    PEDIATRIC BLOOD & CANCER, 2022, 69 (09)
  • [46] Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children's Hospital of Fudan University
    Qian, Xiaowen
    Zhang, Dufei
    Li, Kai
    Chen, Weiming
    Zhuang, Peijun
    Wang, Hongsheng
    Lei, Zhixian
    Li, Yan
    Eldridge, James
    Dong, Kuiran
    Zhai, Xiaowen
    DRUGS-REAL WORLD OUTCOMES, 2025, 12 (01) : 115 - 123
  • [47] Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients-role of maintenance therapy in the real world
    Damlaj, Moussab
    Tlayjeh, Mohamed
    Damlaj, Ahmad
    Alahmari, Bader
    AlSadi, Husam
    Ahmed, Mazin
    AlJubour, Zied
    Alhejazi, Ayman
    Salama, Hend
    Ibrahim, Ayman
    Al Raizah, Abdulrahman
    Bakkar, Mohammed
    Ghori, Abdulraouf
    Al Saleh, Abdullah S.
    Alaskar, Ahmed
    Alzahrani, Mohsen
    BONE MARROW TRANSPLANTATION, 2023, 58 (10) : 1160 - 1162
  • [48] Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand
    Suwannaying, Kunanya
    Techavichit, Piti
    Komvilaisak, Patcharee
    Laoaroon, Napat
    Narkbunnam, Nattee
    Sanpakit, Kleebsabai
    Chiengthong, Kanhatai
    Chotsampancharoen, Thirachit
    Sathitsamitphong, Lalita
    Santong, Chalongpon
    Seksarn, Panya
    Hongeng, Suradej
    Wiangnon, Surapon
    CLINICAL AND EXPERIMENTAL PEDIATRICS, 2022, 65 (09) : 453 - 458
  • [49] Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT
    T Sauer
    G Silling
    C Groth
    F Rosenow
    U Krug
    D Görlich
    G Evers
    J Albring
    R Besoke
    R M Mesters
    C Müller-Tidow
    T Kessler
    T Büchner
    W E Berdel
    M Stelljes
    Bone Marrow Transplantation, 2015, 50 : 485 - 492
  • [50] Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT
    Sauer, T.
    Silling, G.
    Groth, C.
    Rosenow, F.
    Krug, U.
    Goerlich, D.
    Evers, G.
    Albring, J.
    Besoke, R.
    Mesters, R. M.
    Mueller-Tidow, C.
    Kessler, T.
    Buechner, T.
    Berdel, W. E.
    Stelljes, M.
    BONE MARROW TRANSPLANTATION, 2015, 50 (04) : 485 - 492
12345